Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, February 26, 2018
Catalyst Biosciences announced they have entered into a manufacturing agreement with AGC Biologics for the process transfer and commercial scale cGMP manufacturing of CB 2679d.
read more
Wednesday, February 12, 2020
Catalent has signed an agreement with Zumutor Biologics to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.
read more
Catalent has signed an agreement with ViralClear to work on the development of a potential treatment for adults with advanced COVID-19.
read more
Verastem Oncology has received U.S. Food and Drug Administration (FDA) approval for Copiktra (duvelisib) capsules.
read more
Wednesday, September 25, 2019
Catalent and Minerva Neurosciences have entered into a commercial supply agreement for roluperidone, an investigational compound from Minerva, for symptoms of schizophrenia.
read more
OMI Environmental Solutions Inc.®, a company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, implemented SteraMist technology into four ...
read more
Catalent announced an expanded partnership with Janssen Pharmaceutica and Janssen Pharmaceuticals whereby Catalent will increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing ...
read more
Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19.
read more
Catalent has signed an agreement with Cybin to apply Catalent’s proprietary Zydis ODT technology for the delivery of Cybin’s novel deuterated tryptamine.
read more
Catalent and BrainStorm an agreement for the manufacture of NurOwn, BrainStorm’s autologous cellular therapy being investigated for the treatment of ALS.
read more
Catalent announced the company will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222.
read more
Wednesday, October 27, 2021
Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced a $230 million expansion project to add three ...
read more
Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
read more
Tuesday, November 13, 2018
Catalent Pharma Solutions announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019.
read more
Catalent is set to launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs.
read more